Aliases for NMNAT3 Gene
- Nicotinamide Nucleotide Adenylyltransferase 3 2 3 5
- Nicotinate-Nucleotide Adenylyltransferase 3 3 4
- Pyridine Nucleotide Adenylyltransferase 3 3 4
- NMN/NaMN Adenylyltransferase 3 3 4
- NaMN Adenylyltransferase 3 3 4
- NMN Adenylyltransferase 3 3 4
- PNAT-3 3 4
- Nicotinamide/Nicotinic Acid Mononucleotide Adenylyltransferase 3 3
External Ids for NMNAT3 Gene
Previous GeneCards Identifiers for NMNAT3 Gene
This gene encodes a member of the nicotinamide/nicotinic acid mononucleotide adenylyltransferase family. These enzymes use ATP to catalyze the synthesis of nicotinamide adenine dinucleotide or nicotinic acid adenine dinucleotide from nicotinamide mononucleotide or nicotinic acid mononucleotide, respectively. The encoded protein is localized to mitochondria and may also play a neuroprotective role as a molecular chaperone. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene. [provided by RefSeq, Jan 2011]
GeneCards Summary for NMNAT3 Gene
NMNAT3 (Nicotinamide Nucleotide Adenylyltransferase 3) is a Protein Coding gene. Among its related pathways are NAD metabolism and superpathway of tryptophan utilization. GO annotations related to this gene include nucleotidyltransferase activity and nicotinamide-nucleotide adenylyltransferase activity. An important paralog of this gene is NMNAT1.
UniProtKB/Swiss-Prot for NMNAT3 Gene
Catalyzes the formation of NAD(+) from nicotinamide mononucleotide (NMN) and ATP. Can also use the deamidated form; nicotinic acid mononucleotide (NaMN) as substrate with the same efficiency. Can use triazofurin monophosphate (TrMP) as substrate. Can also use GTP and ITP as nucleotide donors. Also catalyzes the reverse reaction, i.e. the pyrophosphorolytic cleavage of NAD(+). For the pyrophosphorolytic activity, can use NAD(+), NADH, NaAD, nicotinic acid adenine dinucleotide phosphate (NHD), nicotinamide guanine dinucleotide (NGD) as substrates. Fails to cleave phosphorylated dinucleotides NADP(+), NADPH and NaADP(+). Protects against axonal degeneration following injury.